American Osteopathic Academy of Addiction Medicine - AOAAM

American Osteopathic Academy of Addiction Medicine - AOAAM Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from American Osteopathic Academy of Addiction Medicine - AOAAM, Addiction Resources Center, 1018 W Madison Stree, Suite 9, Chicago, IL.

American Osteopathic Academy of Addiction Medicine (AOAAM) represents osteopathic physicians involved in the treatment of alcoholism and substance use disorder.
--
https://aoaam.start.page

AOAAM is highlighting the AOA clinical pathway for Addiction Medicine certification as this is the final year the pathwa...
03/27/2026

AOAAM is highlighting the AOA clinical pathway for Addiction Medicine certification as this is the final year the pathway will be available.

Click here to learn more: https://certification.osteopathic.org/addiction-medicine/certification-process/

We are seeking physicians who achieved certification through this pathway, particularly those who pursued it mid-career, to briefly share their experience.

Your perspective could inspire another physician to pursue certification before the opportunity closes.

Contributions may include a short quote, brief testimonial, or short video clip.

If this applies to you, or you know a colleague who may be willing to share their experience, please reach out to melissa@aoaam.org

Now published in the Journal of Addictive Diseases:Heaviness of Smoking Index in Menthol and Non-Menthol SmokersAnalyzin...
03/25/2026

Now published in the Journal of Addictive Diseases:

Heaviness of Smoking Index in Menthol and Non-Menthol Smokers

Analyzing data from 27,131 adult smokers, this study examined whether menthol cigarette use is associated with higher ni****ne dependence using the Heaviness of Smoking Index (HSI).

Findings showed that menthol smokers were more likely to be non-daily smokers and less likely to fall into the high dependence category, with no increased odds of dependence after adjusting for demographics.

These results challenge assumptions that menthol ci******es increase ni****ne dependence.

Read more: 🔗 https://www.tandfonline.com/doi/full/10.1080/10550887.2022.2112495

Since 2021, AOAAM, in collaboration with the Opioid Response Network (ORN), has delivered expert-led education addressin...
03/25/2026

Since 2021, AOAAM, in collaboration with the Opioid Response Network (ORN), has delivered expert-led education addressing substance use disorders and the evolving opioid crisis.

Through the Opioid Response Network ORN Hot Topic Webinar Series:
• 37 webinars delivered
• 27,000+ continuing education credits awarded

These sessions continue to equip healthcare professionals with practical tools to improve addiction care nationwide.

Explore upcoming and on-demand webinars:
Click Here

Funding Acknowledgement

Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from the Substance Abuse and Mental Health Services Administration (SAMHSA). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Now published in the Journal of Addictive Diseases:Machine-learning algorithms predicting retention, overdoses, and mort...
03/20/2026

Now published in the Journal of Addictive Diseases:

Machine-learning algorithms predicting retention, overdoses, and mortality among U.S. veterans treated with buprenorphine for OUD

Using national VA data, this study developed and validated predictive models for treatment retention, overdose, and mortality. Random forest and gradient boosting models showed moderate performance (AUC-ROC 0.72–0.79).

Importantly, no single predictor drove outcomes — reinforcing the complexity of MOUD retention and overdose risk.

Read more:
🔗 https://doi.org/10.1080/10550887.2024.2363035

👥 Become a Mentor with the PCSS-MOUD Mentoring ProgramHelp support your colleagues and strengthen evidence-based care fo...
03/14/2026

👥 Become a Mentor with the PCSS-MOUD Mentoring Program

Help support your colleagues and strengthen evidence-based care for opioid use disorder (OUD).

The PCSS-MOUD Mentoring Program is seeking qualified healthcare professionals to join its mentor network. This program helps clinicians gain confidence and strengthen their clinical practice in the prevention and treatment of opioid use disorder and other substance use disorders.

💡 Why Become a Mentor?

Opioid overdoses continue to impact communities across the United States. Now more than ever, clinicians need support in delivering evidence-based practices for the prevention and treatment of OUD.

By serving as a mentor, you can help expand access to clinical guidance and support for providers caring for patients with OUD and chronic pain.

🔎 Program Highlights

✔ No-cost mentoring program available to all providers
✔ Network of experienced healthcare professionals
✔ Flexible mentoring opportunities via:
• Telephone
• Email
• In-person (when logistically possible)

✅ Ready to apply?
Complete the mentor application online:

🔗 PCSS-MOUD.org

Learn more about PCSS trainings, mentoring, and national resources:
🔗 https://pcssnow.org

Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

📢 Save the Date – Complimentary WebinarAOAAM, in partnership with the Opioid Response Network (ORN), invites healthcare ...
03/13/2026

📢 Save the Date – Complimentary Webinar

AOAAM, in partnership with the Opioid Response Network (ORN), invites healthcare professionals to the next webinar in the ORN Spring 2026 Hot Topics in Addiction Medicine Series.

🗓 May 13, 2026

⏰ 5:00 PM ET

This session will explore the emergence of medetomidine — a highly potent veterinary alpha-2 adrenergic agonist — as an adulterant in the U.S. illicit opioid supply and the implications it may have for clinical management and systems of care.

Join us as we begin to unpack the clinical effects, toxicity, and treatment considerations surrounding this emerging substance.

🔎 Stay tuned!

We’ll be sharing the speaker announcement and additional webinar details soon, including learning objectives and key takeaways.

🔗 Registration is required:

https://education.aoaam.org/products/orn-spring-2026-medetomidine-impacts-on-clinical-management-and-systems-of-care

Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Now published in the Journal of Addictive Diseases:Central sensitization in alcohol use disorder: correlates of pain, ad...
03/13/2026

Now published in the Journal of Addictive Diseases:

Central sensitization in alcohol use disorder: correlates of pain, addiction and health-related quality of life

This study is the first to apply a validated surrogate measure of central sensitization in a clinical sample of individuals with AUD.

The results advance mechanistic understanding of the intersection between chronic pain and alcohol use disorder.

Read the full article:
🔗 https://doi.org/10.1080/10550887.2023.2237396

🎓 Live Webinar Series – Includes CMEJoin us for the 4-hour MOUD DEA Training live webinar, “Understanding Addiction Phar...
03/12/2026

🎓 Live Webinar Series – Includes CME

Join us for the 4-hour MOUD DEA Training live webinar, “Understanding Addiction Pharmacology of Medications for Opioid Use Disorders,” on:

🗓 Saturday, May 2, 2026

⏰ 8:00 AM – 12:15 PM ET

This live training will explore key topics shaping the field of addiction medicine and provide practical insights into the pharmacology and clinical use of medications for opioid use disorders (MOUD).

The session will be led by Dr. Stephen A Wyatt, DO, a Board-Certified Psychiatrist with subspecialty certification in Addiction Psychiatry. Dr. Wyatt currently serves as Psychiatry Faculty at MAHEC in Asheville, NC and is an adjunct professor at the University of North Carolina. He is a past president of AOAAM, Chair of the COPE: The Coalition on Physician Education in Substance Use Disorders, and a clinical expert for the SAMHSA-funded Provider Clinical Support System (PCSS).

💡 Continuing Medical Education (CME) Credits Available

Participants in this program may earn:

✔ Up to 4 AOA Category 1-A Credits
✔ Up to 4 AAFP Credits

Earn valuable continuing education credits while enhancing your professional knowledge in the treatment of opioid use disorder.

📚 Learning Objectives

By the conclusion of this webinar series, attendees will be able to:

• Describe the value of utilizing evidence-based treatment in identifying and caring for patients with substance use disorder
• Prescribe buprenorphine products using a safe and effective management plan
• Improve confidence and comfort in managing patients with opioid use disorder

🎯 Outcomes

At the completion of this program, healthcare providers will be better equipped to prevent, identify, and understand evidence-based treatment approaches for opioid use disorders.

⚠️ Registration is required for each live webinar individually.

If you have not registered for one of our live webinars in the past, please subscribe to AOAAM, then login and register.

🔗 Register here:

https://education.aoaam.org/Public/Catalog/Details.aspx?id=KJoPXiDn%2b0vnzXEdJKCBsA%3d%3d

🔗 Learn more about PCSS resources, trainings, and national updates:

pcssnow.org

Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

📢 Save the Date – Complimentary WebinarAOAAM, in partnership with the Opioid Response Network (ORN), invites you to the ...
03/12/2026

📢 Save the Date – Complimentary Webinar

AOAAM, in partnership with the Opioid Response Network (ORN), invites you to the first webinar in the ORN Spring 2026 Hot Topics in Addiction Medicine Series.

🗓 May 6, 2026
⏰ 5:00 PM ET

This session will explore the rapid diversification of kratom-derived products, including compounds such as 7-hydroxymitragynine, pseudoindoxyl, and related substances, and the growing impact these substances are having on clinical care and public health.

As new kratom-derived compounds continue to emerge, clinicians are increasingly encountering questions about their pharmacology, risks, and implications for the treatment of substance use disorders.

🔎 Stay tuned for upcoming posts revealing our featured speaker and additional details.

🔗 Registration is required:
https://education.aoaam.org/products/orn-spring-2026-update-on-the-diversification-of-kratom-derive…

Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Now Available On-Demand!Su***de risk is significantly elevated among individuals with opioid use disorder (OUD). In this...
03/03/2026

Now Available On-Demand!

Su***de risk is significantly elevated among individuals with opioid use disorder (OUD). In this ORN Summer 2025 session, Max Spaderna, MD examines why — including research findings, intentional opioid overdose, and the clinical challenges of identifying those at risk.

Participants will be able to:
✔ Evaluate su***de risk in individuals with OUD
✔ Explain key associated characteristics
✔ Describe the relationship between intentional overdose and su***de risk
✔ Identify challenges in assessment and prevention

CME Credits Available:
1 AOA Category 1-A Credit | 1 AMA PRA Category 1 Credit™ | 1 AAPA Category 1 CME Credit | 1 Nurses CNE Credit

Participants may earn CME/CNE credit upon completion.

Funding for this initiative was made possible (in part) by grant no. 1H79TI088037 from Substance Abuse and Mental Health Services Administration

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

🔗 https://education.aoaam.org/Public/Catalog/Details.aspx?id=oED8VFlm3ky09PGEb8PhuA%3d%3d

NAV & Associates is proud to support research and initiatives that advance addiction science and promote better outcomes for patients and communities.

***dePrevention

Check out this article from the Journal of Addictive Diseases (JAD):“Inpatient initiation of long-acting injectable bupr...
02/27/2026

Check out this article from the Journal of Addictive Diseases (JAD):

“Inpatient initiation of long-acting injectable buprenorphine at a community hospital: A retrospective case series”

This study highlights the feasibility and safety of initiating long-acting injectable buprenorphine (LAIB) during hospitalization — even with minimal sublingual lead-in.

Key findings:
• 50% attended a follow-up appointment within 30 days (vs. 30% historical baseline)
• 87% received LAIB with fewer than seven days of sublingual buprenorphine
• No precipitated withdrawal after LAIB administration

Hospital-based LAIB may help improve post-discharge engagement in care.

Read more:
🔗 https://lnkd.in/g36uQi9a

From one provider treating 20 patients to a thriving program serving 90 — this is what happens when passion meets suppor...
02/13/2026

From one provider treating 20 patients to a thriving program serving 90 — this is what happens when passion meets support.

In 2020, Andrew Johnstone, APN, FNP, MSN, BC, was the only prescriber in his practice treating patients with opioid use disorder. Today, Jefferson Health has built a compassionate, evidence-based MOUD program that not only supports patients through every stage of recovery — including relapse — but is now helping other clinics do the same.

With support from Pcss-Moud Implementation, the team developed flexible clinical guidance, strengthened partnerships with behavioral health and social services, and built a culture where patients are met with encouragement, not judgment.

“If a patient relapses, that’s okay. We say, ‘I’m proud of you for coming back.’”

This is what whole-person, evidence-based care looks like.

Read the full article here: https://pcssnow.org/real-stories/new-jersey-primary-care-practice-a-model-for-treating-patients-with-oud/

Address

1018 W Madison Stree, Suite 9
Chicago, IL
60607

Website

https://aoaam.org/

Alerts

Be the first to know and let us send you an email when American Osteopathic Academy of Addiction Medicine - AOAAM posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to American Osteopathic Academy of Addiction Medicine - AOAAM:

Shortcuts

Share

Category